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Abstract
A 23-year old woman with acute biphenotypic leukemia (ABL) complained of chest pain with
cough, high fever and hemoptysis during induction chemotherapy, although she had been treated
with anti-biotics and micafungin. We made a clinical diagnosis of invasive pulmonary aspergillosis
(IPA) based on a consolidation in the right upper lung field on a chest radiograph as well as a high
level of serum beta-D-glucan (with no evidence of tuberculosis and candidiasis). We changed her
treatment from micafungin to voriconazole. Later, we discovered an air-crescent sign by CT scan
that supported the diagnosis of IPA. Following voriconazole treatment, clinical symptoms ceased
and abnormal chest shadows improved gradually and concurrently with a recovery of neutrophils.
IPA must be considered in immunocompromised patients with pulmonary infiltrates who do not
respond to broad-spectrum antibiotics. Serological tests and CT findings can aid in early diagnosis
of IPA, which, along with treatment for IPA, will improve clinical outcomes.
KEYWORDS: invasive pulmonary aspergillosis, voriconazole, acute biphenotypic leukemia, febrile
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A 23-year old woman with acute biphenotypic leukemia (ABL) complained of chest pain with cough,  
high fever and hemoptysis during induction chemotherapy,  although she had been treated with anti-
biotics and micafungin.  We made a clinical diagnosis of invasive pulmonary aspergillosis (IPA) based 
on a consolidation in the right upper lung ﬁeld on a chest radiograph as well as a high level of serum 
ｹ-D-glucan (with no evidence of tuberculosis and candidiasis).  We changed her treatment from mica-
fungin to voriconazole.  Later,  we discovered an air-crescent sign by CT scan that supported the 
diagnosis of IPA.  Following voriconazole treatment,  clinical symptoms ceased and abnormal chest 
shadows improved gradually and concurrently with a recovery of neutrophils.  IPA must be consid-
ered in immunocompromised patients with pulmonary inﬁltrates who do not respond to broad-spec-
trum antibiotics.  Serological tests and CT ﬁndings can aid in early diagnosis of IPA,  which,  along 
with treatment for IPA,  will improve clinical outcomes.
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nvasive pulmonary aspergillosis (IPA) is a 
severe complication occurring in patients with 
neutropenia induced by intensive chemotherapy for 
hematologic malignancies.  The diagnosis of IPA is 
often delayed,  and eﬀective therapeutic agents are 
limited,  resulting in a poor prognosis with a mortality 
rate of 55ｵ to 80ｵ [1].  Cases of IPA complicating 
hematologic malignancies have recently increased in 
number [2].  It has been reported that the incidence 
of IPA with acute leukemia is 25ｵ to 55ｵ and that 
the incidence of IPA after allogenic bone marrow 
transplantations is 4ｵ to 10ｵ,  with a mortality rate 
of 80ｵ to 90ｵ [3].  Recently,  new antifungal agents 
such as voriconazole (VRCZ) and echinocandins,  
including caspofungin and micafungin (MCFG),  have 
been clinically evaluated [4,  5].  VRCZ is one of the 
azoles,  a powerful antifungal agent,  especially against 
Aspergillus spp.  [6].  In western countries,  VRCZ is 
widely used in the second prophylaxis,  empirical,  or 
target therapy among patients with hematologic malig-
nancies complicated with febrile neutropenia associ-
ated with intensive chemotherapy [6].  However,  the 
eﬃcacy of VRCZ as initial therapy for IPA with 
neutropenia has not been investigated in Japan.  We 
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report,  herein,  a successful treatment of IPA using 
VRCZ in a patient with acute biphenotypic leukemia 
(ABL).
Case Report
　 In August,  2005 a 23-year-old woman was admitted 
to our hospital with fever,  general fatigue,  and ane-
mia.  Hematological tests revealed a white blood cell 
count of 6.8×109/L,  with 8ｵ neutrophils and 26ｵ 
blast cells,  and a hemoglobin level of 8.0g/dL.  Bone 
marrow aspiration yielded a nuclear cell count of 395
×109/L with 95.0ｵ blast cells.  The blast cells were 
negative for myeloperoxidase but positive for cyto-
plasmic CD3 (cyCD3),  CD5,  CD7,  CD13,  CD33,  
CD34,  CD117 and HLA-DR.  Cytogenetic analysis of 
a bone marrow specimen revealed an abnormal karyo-
type in 24 of 24 cells of 46,  XX,  t (12; 19) 
(p13; p11),  add (1) (p34),  del (5) (q22q35),  del (7) 
(q32q34),  add (11) (p15),  add (16) (p13).  Thus,  this 
patient was given a diagnosis of acute biphenotypic 
leukemia (ABL).  Remission-induction chemotherapy,  
consisting of idarubicin and cytosine arabinoside,  was 
initiated (Fig.  1).  For antifungal prophylaxis,  ﬂucon-
azole was administered.  On the 16th day of chemo-
therapy she experienced febrile neutropenia,  so cef-
tazidime and amikacin were administered.  Because the 
high fever continued,  micafungin (150mg once a day,  
drip infusion) was added.  Several tests,  such as blood 
and sputum culture and polymerase chain reaction 
(PCR) for tuberculosis,  were all negative.  On the 
22nd day of chemotherapy,  the patient complained of 
right chest pain with a cough and hemoptysis.  
Although the neutrophil count had recovered to 2.0×
109/L,  she experienced dyspnea and hypoxia (pulse 
oximeter oxygen saturation: SpO2 90ｵ on room air).  
A chest radiograph revealed patchy opacities and a CT 
scan revealed a mass-like lesion in the right upper lung 
ﬁeld.  The level of β-D-glucan (Fungitec G test MK) 
was elevated (34.9pg/ml),  and a serum Candida-
antigen test was negative.  Five days later,  a chest 
x-ray revealed a consolidation (Fig.  2A).  We could not 
perform a transbronchial lung biopsy (TBLB) or a 
bronchoalveolar lavage (BAL) because the patient was 
in poor systemic condition and had severe hypoxia.  We 
made a clinical diagnosis of IPA based on our ﬁndings 
thus far.  We adjusted her treatment from micafungin 
to VRCZ,  which resulted in an elimination of the 
clinical symptoms.  One week after the initiation of 
VRCZ treatment,  the neutrophil count had fully 
recovered but CT scan revealed a mass with a cavity 
surrounded by ground-glass opacity that indicated 
typical halo and air-crescent signs (Fig.  2B).  Three 
weeks after the start of VRCZ treatment,  the patient 
was switched from drip infusion to oral administration 
because abnormal chest shadows improved gradually.  
In September,  2005 bone marrow aspiration ﬁndings 
revealed complete remission.  In October,  2005 the 
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Chemotherapy AraC
IDA VRCZ 400mg/day (iv)
Antifungal
Treatment FLCZ 200mg/day (po)
MCFG 150mg/day (iv) VRCZ 300mg/day (po)
Chest X-ray
Fever, Cough and Chest pain
NCC 2.85
Blast 5.0%, karyotype 46XX
NCC 39.5
Blast 95.0%
2.534.9βD-Glucan (pg/ml)
18000
12000
6000
0
WBC (/mm3)
Fig. 1　 Clinical course of the patient.  AraC indicates cytosine arabinoside; IDA,  idarubicin; FLCZ,  ﬂuconazole; MCFG,  
micafungin; VRCZ,  voriconazole; NCC,  nuclear cell count.
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mass with halo and air crescent signs remarkably 
improved on a chest radiograph and a CT scan (Fig.  
2C and 2D).  Since then,  no recurrence of IPA has 
been observed during 3 courses of consolidation che-
motherapies because oral VRCZ was continued for 
antifungal prophylaxis.
Discussion
　 Our case highlights a successful treatment of IPA 
in an immunocompromised patient with ABL.  In many 
cases,  a delayed diagnosis of IPA leads to more 
severe disease or even death.  Despite recent advances 
in antifungal treatment,  clinical outcomes are still 
generally considered to be inadequate [7] with the 
best reported response rates in the range of 50-60ｵ 
[6].  Response to treatment and survival can poten-
tially be improved if speciﬁc antifungal treatment for 
IPA is initiated at an early stage of infection.  
However,  an early diagnosis of IPA based on histo-
pathological or mycological evidence can be diﬃcult to 
establish [8].  Sputum cultures are neither sensitive 
nor speciﬁc; positive sputum cultures do not always 
correlate with invasive disease,  and negative sputum 
cultures are common in patients with proven IPA [9].  
Indeed,  in another report,  a culture of BAL remained 
negative in 70ｵ of IPA cases with neutropenia [10].  
Moreover,  in a large number of patients with hemato-
logical malignancy who are in poor systemic condition,  
it is diﬃcult to perform invasive examinations such as 
TBLB and BAL.  Therefore,  to make an accurate 
diagnosis of deep fungal infection,  investigative eﬀorts 
have focused on molecular and serological diagnostic 
techniques that determine the presence of fungal cell-
wall constituents such as galactomannan and β
-D-glucan antigens.  For diagnosis of invasive asper-
gillosis in immunocompromised patients,  the rates of 
sensitivity and speciﬁcity of serological tests were 
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Fig. 2　 Chest X-ray and CT evaluation of the patient.  A,  Chest X-ray on September 20,  showing pneumonia in the right upper lung; B,  
CT scan of chest demonstrates typical air-crescent signs and many consolidations in the right pulmonary lobe at one week after the start 
of VRCZ treatment; C,  Chest X-ray on October 5,  showing improvement of pneumonia; D,  CT scan of chest demonstrates improvement 
at 3 weeks after the start of VRCZ treatment.
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70ｵ to 90ｵ and 84ｵ to 86ｵ,  respectively [11].  
Although β-D-glucan is present in other pathogenic 
fungi such as Candida species,  measurement of this 
antigen in blood may be a useful preliminary screening 
tool for invasive aspergillosis.  Extensive eﬀorts have 
been made to detect the DNA of the Aspergillus species,  
but a lack of technical standardization and a relatively 
poor understanding of DNA release and kinetics con-
tinue to hamper the broad applicability of this tech-
nique [12].
　 CT scans may be able to detect lung involvement at 
an early stage of IPA [13].  The halo sign,  a macro 
nodule (＞1cm in diameter) surrounded by a perimeter 
of ground-grass opacity,  is regarded to be an early 
indicator of IPA [14] and has been incorporated into 
the inclusion criteria of clinical studies [6].  Syste-
matic CT screening for the halo sign in high-risk 
patients has been recommended because the initiation 
of antifungal treatment on the basis of this ﬁnding may 
lead to better outcomes [15].  The present patient was 
diagnosed with IPA as a clinically documented fungal 
infection based on a mass in chest CT scans,  in addi-
tion to high levels of serum β-D-glucan.  For early 
detection of IPA in immunocompromised patients,  the 
use of a combination of blood samples and CT scan 
appears to be the most promising approach.
　 For the patient in this study,  chest x-rays,  CT 
ﬁndings,  and high levels of serum β-D-glucan led to a 
clinical diagnosis of IPA,  and VRCZ treatment was 
eﬀective as an early-presumptive therapy.  The key to 
obtaining a favorable outcome was early diagnosis,  a 
full recovery of neutrophils,  and aggressive antifungal 
treatment with VRCZ or lipid-based amphotericin-B 
for IPA.  Administration of these antifungal agents 
should be started as a presumptive therapy for IPA if 
clinical signs,  serological results,  chest x-rays or CT 
ﬁndings are suggestive of IPA.
　 In conclusion,  IPA should be considered in immu-
nocompromised patients with pulmonary inﬁltrates who 
do not respond to broad-spectrum antibiotics.  Sero-
logical tests and CT ﬁndings aid in an early diagnosis 
of IPA which,  along with intensive treatment,  will 
improve clinical outcomes.
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